Health Canada denied dozens of healthcare practitioners access to psilocybin therapy training by rejecting their section 56 exemption applications. Now, clinical trials will likely be the only way to get experience with the psychedelic.
TheraPsil, the non-profit that helped with the applications, says that this will impact over one thousand practitioners on their waitlist for psilocybin training and several thousand patients seeking care.
Entheon Biomedical (ENBI) received approval for a phase I DMT trial and will begin screening patients this month. The trial, which will be conducted in the Netherlands, will gather essential safety and dosing data needed for a phase II study on DMT for nicotine addiction.
New research suggests that microdosing doesn’t cause withdrawal symptoms. But can it ease withdrawals from other substances?
MacEwan University researchers found that zebrafish showed increased anxiety behaviour during withdrawal from alcohol, consistent with symptoms that humans experience.
However, when the zebrafish were given microdoses of LSD for 10 days (by putting them in a “dosing tank” for a precise period of time), there were no observed behavioural changes. This indicates that microdosing is not addictive and does not cause withdrawal symptoms.
A study that’s currently underway will examine LSD microdoses on alcohol withdrawal symptoms.
PharmaTher (PHRM) is developing a treatment for a rare, seizure-inducing disorder called Status Epilepticus using ketamine. This week, it was granted a designation that will save them millions of dollars in the process.
It’s called an Orphan Drug Designation and it gives the company potential tax credits, grant eligibility, and marketing exclusivity, and waives a $2.4M New Drug Application fee. It’s designed to incentivize R&D of treatments for rare conditions.
PharmaTher previously received the designation for ketamine to treat ALS and complex regional pain syndrome too!
A second ballot initiative has been filed in Colorado to decriminalize the possession, cultivation, and gifting of psilocybin, psilocyn, ibogaine, mescaline and DMT. It would also legalize guided psychedelic sessions for therapeutic or spiritual purposes.
The first measure is focused on legalizing psilocybin and creating psilocybin healing centers.